Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma

Modern Pathology

Volumn 22, Issue 2, 2009, Pages 197-205

  Flavin, Richard J ^a,c   Smyth, Paul C ^a   Laios, Alexandros ^a   O'Toole, Sharon A ^a   Barrett, Ciara ^a   Finn, Stephen P ^a   Russell, Susan ^a   Ring, Martina ^a   Denning, Karen M ^a   Li, Jinghuan ^a   Aherne, Sinead T ^a   Sammarae, Dania A ^a   Aziz, Natasha A ^a   Alhadi, Araibi ^a   Sheppard, Brian L ^a   Lao, Kai ^b   Sheils, Orla M ^a   O'Leary, John J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b APPLIED BIOSYSTEMS   (United States)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

Chromosome 17; microRNA; Primary peritoneal carcinoma

Indexed keywords

MICRORNA; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CARCINOMA; CHROMOSOME 17P; CONTROLLED STUDY; DOWN REGULATION; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; OVARY CARCINOMA; PERITONEUM CANCER; PRIMARY PERITONEAL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHROMOSOMES, HUMAN, PAIR 17; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICRORNAS; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 59149091973     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.135     Document Type: Article

References (88)

1. Lele SB, Piver MS, Matharu J, et al. Peritoneal papillary carcinoma. Gynecol Oncol 1988;31:315-320.
2. Dalrymple JC, Bannatyne P, Russell P, et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer 1989;64:110-115.
3. Fromm GL, Gershenson DM, Silva EG. Papillary serous carcinoma of the peritoneum. Obstet Gynecol 1990;75:89-95.
4. Bandera CA, Muto MG, Welch WR, et al. Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum. Oncogene 1998;16:3455-3459.
5. Huang LW, Garrett AP, Schorge JO, et al. Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum. Am J Clin Pathol 2000;114:93-99.
6. Wojnarowicz PM, Breznan A, Arcand SL, et al. Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes. Int J Gynecol Cancer 2007, Nov 19; e-pub ahead of print.
7. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-15529.
8. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65:9628-9632.
9. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67:8699-8707.
10. Karube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005;96:111-115.
11. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-838.
12. Michael MZ, O'Connor SM, van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003;1:882-891.
13. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-3756.
14. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68:425-433.
15. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003;113:673-676.
16. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
17. Grosshans H, Slack FJ. Micro-RNAs: small is plentiful. J Cell Biol 2002;156:17-21.
18. Calin GA, Cimmino A, Fabbri M, et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 2008;105:5166-5171.
19. Zhang L, Huang J, Yang N, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006;103:9136-9141.
20. Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993;50:347-351.
21. Smyth P, Finn S, Cahill S, et al. ret/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic Irish cohort of papillary thyroid carcinoma. Int J Surg Pathol 2005;13:1-8.
22. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000;19:7-15.
23. Lao K, Xu NL, Yeung V, et al. Multiplexing RT-PCR for the detection of multiple miRNA species in small samples. Biochem Biophys Res Commun 2006;343:85-89.
24. Nisolle M, Gillerot S, Casanas-Roux F, et al. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod 1999;14:2844-2850.
25. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102:13944-13949.
26. Eccles DM, Brett L, Lessells A, et al. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 1992;65:40-44.
27. Eccles DM, Cranston G, Steel CM, et al. Allele losses on chromosome 17 in human epithelial ovarian carcinoma. Oncogene 1990;5:1599-1601.
28. Lee JH, Kavanagh JJ, Wildrick DM, et al. Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas. Cancer Res 1990;50:2724-2728.
29. Sato T, Saito H, Morita R, et al. Allelotype of human ovarian cancer. Cancer Res 1991;51:5118-5122.
30. Eltabbakh GH, Piver MS. Extraovarian primary peritoneal carcinoma. Oncology (Williston Park, NY) 1998;12:813-819; discussion 20, 25-26.
31. Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report. Am J Obstet Gynecol 1959;77:197-200.
32. Bloss JD, Brady MF, Liao SY, et al. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma - a Gynecologic Oncology Group Study. Gynecol Oncol 2003;89:148-154.
33. Eltabbakh GH, Piver MS, Natarajan N, et al. Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet Gynecol 1998;91:254-259.
34. Barda G, Menczer J, Chetrit A, et al. Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study. Am J Obstet Gynecol 2004;190:1039-1045.
35. Ben-Baruch G, Sivan E, Moran O, et al. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma. Gynecol Oncol 1996;60:393-396.
36. Dubernard G, Morice P, Rey A, et al. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma. Eur J Surg Oncol 2004;30:976-981.
37. Eisenhauer EL, Sonoda Y, Levine DA, et al. Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma. Am J Obstet Gynecol 2008;198:213 e1-7.
38. Jordan SJ, Green AC, Whiteman DC, et al. Risk factors for benign serous and mucinous epithelial ovarian tumors. Obstet Gynecol 2007;109:647-654.
39. Cass I, Baldwin RL, Fasylova E, et al. Allelotype of papillary serous peritoneal carcinomas. Gynecol Oncol 2001;82:69-76.
40. Muto MG, Welch WR, Mok SC, et al. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res 1995;55:490-492.
41. Schorge JO, Muto MG, Welch WR, et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 1998;90:841-845.
42. Jacobs IJ, Kohler MF, Wiseman RW, et al. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 1992;84:1793-1798.
43. Li S, Han H, Resnik E, et al. Advanced ovarian carcinoma: molecular evidence of unifocal origin. Gynecol Oncol 1993;51:21-25.
44. Mok CH, Tsao SW, Knapp RC, et al. Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res 1992;52:5119-5122.
45. Pejovic T, Heim S, Mandahl N, et al. Bilateral ovarian carcinoma: cytogenetic evidence of unicentric origin. Int J Cancer 1991;47:358-361.
46. Tsao SW, Mok CH, Knapp RC, et al. Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas. Gynecol Oncol 1993;48:5-10.
47. Karlan BY, Baldwin RL, Lopez-Luevanos E, et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 1999;180:917-928.
48. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001;38:87-95.
49. Crum CP, Drapkin R, Kindelberger D, et al. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 2007;5:35-44.
50. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007;19:3-9.
51. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31:161-169.
52. Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008;14:2690-2695.
53. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007;297:1901-1908.
54. Bruchova H, Yoon D, Agarwal AM, et al. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol 2007;35:1657-1667.
55. Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-1801.
56. Chen Y, Stallings RL. Differential patterns of micro-RNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007;67:976-983.
57. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-7070.
58. Lui WO, Pourmand N, Patterson BK, et al. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res 2007;67:6031-6043.
59. Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006;25:2537-2545.
60. Porkka KP, Pfeiffer MJ, Waltering KK, et al. MicroRNA expression profiling in prostate cancer. Cancer Res 2007;67:6130-6135.
61. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-436.
62. Subramanian S, Lui WO, Lee CH, et al. MicroRNA expression signature of human sarcomas. Oncogene 2008;27:2015-2026.
63. Wang T, Zhang X, Obijuru L, et al. A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer 2007;46:336-347.
64. Flavin RJ, Smyth PC, Finn SP, et al. Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol 2008;21:676-684.
65. Lu L, Katsaros D, de la Longrais IA, et al. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 2007;67:10117-10122.
66. Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008;40:43-50.
67. Casey G, Lopez ME, Ramos JC, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996;13:1971-1981.
68. Herod JJ, Eliopoulos AG, Warwick J, et al. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996;56:2178-2184.
69. Teneriello MG, Ebina M, Linnoila RI, et al. p53 and Kiras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993;53:3103-3108.
70. Chen LM, Yamada SD, Fu YS, et al. Molecular similarities between primary peritoneal and primary ovarian carcinomas. Int J Gynecol Cancer 2003;13:749-755.
71. Halperin R, Zehavi S, Hadas E, et al. Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma. Int J Gynecol Pathol 2001;20:341-345.
72. Kowalski LD, Kanbour AI, Price FV, et al. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma. Cancer 1997;79:1587-1594.
73. Soslow RA, Slomovitz BM, Saqi A, et al. Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in mullerian serous carcinomas: clinical divergence without immunophenotypic differences. Gynecol Oncol 2000;79:430-437.
74. Aman P, Pejovic T, Wennborg A, et al. Mapping of the 19p13 breakpoint in an ovarian carcinoma between the INSR and TCF3 loci. Genes Chromosomes Cancer 1993;8:134-136.
75. Bourguignon LY, Gilad E, Peyrollier K. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. J Biol Chem 2007;282:19426-19441.
76. Bourguignon LY, Peyrollier K, Gilad E, et al. Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells. J Biol Chem 2007;282:1265-1280.
77. Bourguignon LY, Zhu H, Zhou B, et al. Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J Biol Chem 2001;276:48679- 48692.
78. Cristiano BE, Chan JC, Hannan KM, et al. A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. Cancer Res 2006;66:11718-11725.
79. Davidson B, Berner A, Nesland JM, et al. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J Pathol 2000;192:460-469.
80. Davies BR, Worsley SD, Ponder BA. Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology 1998;32:69-80.
81. Fujimoto J, Ichigo S, Hirose R, et al. Expression of E-cadherin and alpha- and beta-catenin mRNAs in ovarian cancers. Cancer Lett 1997;115:207-212.
82. McPhillips F, Mullen P, MacLeod KG, et al. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. Carcinogenesis 2006;27:729-739.
83. Melichar B, Nash MA, Lenzi R, et al. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin Exp Immunol 2000;119:19-27.
84. Naora H, Yang YQ, Montz FJ, et al. A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells. Proc Natl Acad Sci USA 2001;98:4060-4065.
85. Pangas SA, Li X, Umans L, et al. Conditional deletion of Smad1 and Smad5 in somatic cells of male and female gonads leads to metastatic tumor development in mice. Mol Cell Biol 2008;28:248-257.
86. Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 30-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001;61:7426-7429.
87. Song H, Hogdall E, Ramus SJ, et al. Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival. Clin Cancer Res 2008;14:1090-1095.
88. Weichert W, Gekeler V, Denkert C, et al. Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis. Int J Oncol 2003;23:633-639.